[Single-agent trial with epirubicin in hematological malignancies].
Twelve patients with hematological malignancies were treated with epirubicin and ten patients were evaluable. One out of our four patients with ALL, who had a previous therapy of anthracycline, achieved a partial remission (PR: 25%). In two patients with AML, remission was not obtained. Of four patients with NHL, one with B-cell lymphoma achieved complete remission (CR) and one with ATLL partial remission (CR + PR: 50%). Stomatitis was observed as a major side effect in three patients with acute leukemia and in one with NHL. In conclusion, our trial seems to show the efficacy of epirubicin in lymphoid malignancies.
Kobayashi
T
T
Tanaka
I
I
Ohta
C
C
Katayama
N
N
Ohno
T
T
Uchida
T
T
Shimizu
N
N
Furuta
I
I
Matsuoka
N
N
Shima
N
N
D000208:Acute Disease; D000328:Adult; D000368:Aged; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D015251:Epirubicin; D005260:Female; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
D015251:Epirubicin; D004317:Doxorubicin